These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 27658762)

  • 1. Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study.
    Krause K; Tsianakas A; Wagner N; Fischer J; Weller K; Metz M; Church MK; Maurer M
    J Allergy Clin Immunol; 2017 Apr; 139(4):1311-1320. PubMed ID: 27658762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome.
    de Koning HD; Schalkwijk J; van der Ven-Jongekrijg J; Stoffels M; van der Meer JW; Simon A
    Ann Rheum Dis; 2013 Oct; 72(10):1634-8. PubMed ID: 23087179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canakinumab in Schnitzler syndrome.
    Vanderschueren S; Knockaert D
    Semin Arthritis Rheum; 2013 Feb; 42(4):413-6. PubMed ID: 22901459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review.
    Betrains A; Staels F; Vanderschueren S
    Semin Arthritis Rheum; 2020 Aug; 50(4):636-642. PubMed ID: 32502728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.
    Koné-Paut I; Lachmann HJ; Kuemmerle-Deschner JB; Hachulla E; Leslie KS; Mouy R; Ferreira A; Lheritier K; Patel N; Preiss R; Hawkins PN;
    Arthritis Res Ther; 2011; 13(6):R202. PubMed ID: 22152723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study.
    Krause K; Weller K; Stefaniak R; Wittkowski H; Altrichter S; Siebenhaar F; Zuberbier T; Maurer M
    Allergy; 2012 Jul; 67(7):943-50. PubMed ID: 22583335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab.
    Salcedo-Mingoarranz AL; Dorado-Fernández M; García-Martínez S; Collado-Ramos P; Silvestre-Torner N
    J Dermatolog Treat; 2023 Dec; 34(1):2242705. PubMed ID: 37551725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory serum immunoglobulin M elevation during anti-interleukin (IL)-1- or IL-6-targeted treatment in four patients with Schnitzler syndrome.
    Takimoto-Ito R; Kambe N; Kogame T; Otsuka A; Nomura T; Izawa K; Tabuchi Y; Yoshifuji H; Takeuchi Y; Kabashima K
    J Dermatol; 2021 Nov; 48(11):1789-1792. PubMed ID: 34435697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Urticaria in a Phase II Randomized Double-Blind Placebo-Controlled Single-Center Study.
    Maul JT; Distler M; Kolios A; Maul LV; Guillet C; Graf N; Imhof L; Lang C; Navarini AA; Schmid-Grendelmeier P
    J Allergy Clin Immunol Pract; 2021 Jan; 9(1):463-468.e3. PubMed ID: 32827729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schnitzler's Syndrome-Diagnostic Experience, Approaches to Therapy, and Patient Management according to a Multicenter Russian Cohort.
    Salugina SO; Torgashina AV; Borzova EY; Rameev VV; Gorodetsky VR; Fedorov ES; Muravyova NV
    Dokl Biochem Biophys; 2024 Aug; 517(1):214-227. PubMed ID: 38861148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of Schnitzler's syndrome without monoclonal gammopathy successfully treated with canakinumab.
    Fujita Y; Asano T; Sakai A; Norikawa N; Yamamoto T; Matsumoto H; Sato S; Temmoku J; Yashiro-Furuya M; Matsuoka N; Watanabe H; Migita K
    BMC Musculoskelet Disord; 2021 Mar; 22(1):257. PubMed ID: 33685423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial.
    Weickert TW; Jacomb I; Lenroot R; Lappin J; Weinberg D; Brooks WS; Brown D; Pellen D; Kindler J; Mohan A; Wakefield D; Lloyd AR; Stanton C; O'Donnell M; Liu D; Galletly C; Shannon Weickert C
    Brain Behav Immun; 2024 Jan; 115():191-200. PubMed ID: 37848096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
    De Benedetti F; Gattorno M; Anton J; Ben-Chetrit E; Frenkel J; Hoffman HM; Koné-Paut I; Lachmann HJ; Ozen S; Simon A; Zeft A; Calvo Penades I; Moutschen M; Quartier P; Kasapcopur O; Shcherbina A; Hofer M; Hashkes PJ; Van der Hilst J; Hara R; Bujan-Rivas S; Constantin T; Gul A; Livneh A; Brogan P; Cattalini M; Obici L; Lheritier K; Speziale A; Junge G
    N Engl J Med; 2018 May; 378(20):1908-1919. PubMed ID: 29768139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of Schnitzler syndrome with canakinumab.
    Pesek R; Fox R
    Cutis; 2014 Sep; 94(3):E11-2. PubMed ID: 25279482
    [No Abstract]   [Full Text] [Related]  

  • 15. [Schnitzler syndrome: A review of literature, the authors' observation, and experience with the interleukin-1 inhibitor canakinumab].
    Salugina SO; Gorodetsky VR; Fedorov ES; Lopatina NE; Evsikova MD
    Ter Arkh; 2017; 89(11):111-115. PubMed ID: 29260755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.
    Kuemmerle-Deschner JB; Hachulla E; Cartwright R; Hawkins PN; Tran TA; Bader-Meunier B; Hoyer J; Gattorno M; Gul A; Smith J; Leslie KS; Jiménez S; Morell-Dubois S; Davis N; Patel N; Widmer A; Preiss R; Lachmann HJ
    Ann Rheum Dis; 2011 Dec; 70(12):2095-102. PubMed ID: 21859692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of canakinumab in the cryopyrin-associated periodic syndrome.
    Lachmann HJ; Kone-Paut I; Kuemmerle-Deschner JB; Leslie KS; Hachulla E; Quartier P; Gitton X; Widmer A; Patel N; Hawkins PN;
    N Engl J Med; 2009 Jun; 360(23):2416-25. PubMed ID: 19494217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Schnitzler syndrome].
    Gellrich FF; Günther C
    Hautarzt; 2018 Sep; 69(9):761-772. PubMed ID: 30167710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Schnitzler syndrome: diagnostics and treatment].
    Szturz P; Adam Z; Sedivá A; Fojtík Z; Corbová D; Neubauer J; Prásek J; Hájek R; Mayer J
    Klin Onkol; 2011; 24(4):271-7. PubMed ID: 21905617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.
    Schlesinger N; Alten RE; Bardin T; Schumacher HR; Bloch M; Gimona A; Krammer G; Murphy V; Richard D; So AK
    Ann Rheum Dis; 2012 Nov; 71(11):1839-48. PubMed ID: 22586173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.